

Beta Nerve Growth Factor (Beta NGF or NGF) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/B7F037BD8AA1EN.html>

Date: February 2022

Pages: 50

Price: US\$ 3,500.00 (Single User License)

ID: B7F037BD8AA1EN

Abstracts

Beta Nerve Growth Factor (Beta NGF or NGF) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Beta Nerve Growth Factor (Beta NGF or NGF) pipeline Target constitutes close to 14 molecules. Out of which approximately 14 molecules are developed by Companies. The latest report Beta Nerve Growth Factor (Beta NGF or NGF) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update, outlays comprehensive information on the Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Beta Nerve Growth Factor (Beta NGF or NGF) - Nerve growth factor is a neurotrophic factor involved in the regulation of growth, maintenance, proliferation, and survival of certain target neurons. It inhibits metalloproteinase dependent proteolysis of platelet glycoprotein VI. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 1, 2, 5 and 2 respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Ophthalmology, Dermatology, Hematological Disorders, Immunology and Musculoskeletal Disorders which include indications Pain, Cancer Pain, Osteoarthritis Pain, Amyotrophic Lateral Sclerosis, Back Pain, Cardiac Arrest, Diabetic Neuropathic

Pain, Glaucoma, Keratitis, Lung Transplant Rejection, Myocardial Infarction, Optic Nerve Injury, Osteoarthritis, Parkinson's Disease, Peripheral Nerve Injury, Post-Operative Pain, Pressure Ulcers, Retinitis Pigmentosa (Retinitis), Sicca Syndrome (Sjogren) and Sickle Cell Disease.

Furthermore, this report also reviews key players involved in Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Beta Nerve Growth Factor (Beta NGF or NGF)

The report reviews Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics and enlists all their major and minor projects

The report assesses Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Beta Nerve Growth Factor (Beta NGF or NGF) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Beta Nerve Growth Factor (Beta NGF or NGF) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Beta Nerve Growth Factor (Beta NGF or NGF) - Overview

Beta Nerve Growth Factor (Beta NGF or NGF) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Beta Nerve Growth Factor (Beta NGF or NGF) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Beta Nerve Growth Factor (Beta NGF or NGF) - Companies Involved in Therapeutics Development

Akeso Inc

AstraZeneca Plc

Chengdu Easton Biopharmaceuticals Co Ltd

Dartsbio Pharmaceutical (Guangdong) Co Ltd

Fujimoto Pharmaceutical Corp

MimeTech Srl

Regeneron Pharmaceuticals Inc

Shandong Boan Biotechnology Co Ltd

Staidson BioPharma Inc

Zhuhai Trinomab Biotechnology Co Ltd

Beta Nerve Growth Factor (Beta NGF or NGF) - Drug Profiles

AK-115 - Drug Profile

Product Description

Mechanism Of Action

DS-002 - Drug Profile

Product Description

Mechanism Of Action

History of Events

EP-9001A - Drug Profile

Product Description

Mechanism Of Action

fasinumab - Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene Therapy to Activate NGF for Diabetic Neuropathy and Peripheral Nerve Injury -

Drug Profile

Product Description

Mechanism Of Action

MEDI-7352 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Monoclonal Antibody to Target NGF beta in Chronic Back Pain, Cancer Pain and

Osteoarthritis - Drug Profile

Product Description

Mechanism Of Action

MT-2 - Drug Profile

Product Description

Mechanism Of Action

History of Events

RBM-004 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Recombinant Protein to Activate NGF Beta for Optic Nerve Injury - Drug Profile

Product Description

Mechanism Of Action

TNM-009 - Drug Profile

Product Description

Mechanism Of Action

TNM-010 - Drug Profile

Product Description

Mechanism Of Action

TNM-011 - Drug Profile

Product Description

Mechanism Of Action

udonitrectag - Drug Profile

Product Description

Mechanism Of Action

History of Events

Beta Nerve Growth Factor (Beta NGF or NGF) - Dormant Products

Beta Nerve Growth Factor (Beta NGF or NGF) - Discontinued Products

Beta Nerve Growth Factor (Beta NGF or NGF) - Product Development Milestones

Featured News & Press Releases

Feb 10, 2022: Approval of clinical trial of NGF monoclonal antibody (AK115) for the treatment of pain (including cancer pain) firstly introduced by Akeso in the field of pain

Jan 01, 2021: Congratulations to DartsBio Pharmaceutical for analgesic DS002 injection approved for clinical trial by NMPA

Dec 05, 2018: Recordati receives orphan drug designation for its investigational treatment for neurotrophic keratitis

Aug 17, 2018: Fasinumab Phase III osteoarthritis trial meets endpoints

Aug 17, 2017: Notice of the Start of a Japanese Phase 2/3 Clinical Study of the Anti-NGF Antibody MT-5547 in Osteoarthritis

Oct 17, 2016: Regeneron and Teva Provide Update on Fasinumab Clinical Development Programs

May 02, 2016: Regeneron Announces Positive Topline Results from Phase 2/3 Fasinumab Study in Patients with Osteoarthritis Pain

Dec 27, 2010: FDA Halts Development Of Regeneron's Pain Drug

May 12, 2010: Regeneron Provides Initial Data On REGN475

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Akeso Inc, 2022

Pipeline by AstraZeneca Plc, 2022

Pipeline by Chengdu Easton Biopharmaceuticals Co Ltd, 2022

Pipeline by Dartsbio Pharmaceutical (Guangdong) Co Ltd, 2022

Pipeline by Fujimoto Pharmaceutical Corp, 2022

Pipeline by MimeTech Srl, 2022

Pipeline by Regeneron Pharmaceuticals Inc, 2022

Pipeline by Shandong Boan Biotechnology Co Ltd, 2022

Pipeline by Staidson BioPharma Inc, 2022

Pipeline by Zhuhai Trinomab Biotechnology Co Ltd, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Beta Nerve Growth Factor (Beta NGF or NGF) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/B7F037BD8AA1EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B7F037BD8AA1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

